ArticleGynecologic oncology reports2025
Use of doxorubicin and trabectedin in low-grade endometrial stromal sarcoma: A case report.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-grade endometrial stromal sarcoma (LG-ESS) is the most common type of endometrial stromal malignancy, yet treatment options are limited, particularly in advanced or recurrent cases that are resistant to hormonal therapy. Case Presentation: We describe a 48-year-old patient with recurrent stage IVB LG-ESS who was treated with a combination of doxorubicin and trabectedin, followed by trabectedin maintenance; a protocol extrapolated from leiomyosarcoma treatment. Following failure to hormonal therapy, this regimen demonstrated disease stabilization, particularly in pelvic metastases. Conclusion: Our results highlight the potential role of this chemotherapy combination in hormonal therapy-resistant LG-ESS, a malignancy with limited systemic therapeutic options. This is the first reported case of LG-ESS achieving prolonged stable disease with doxorubicin-trabectedin therapy and trabectedin maintenance. Given the manageable toxicity profile and encouraging tumor control, further studies should explore its potential role in LG-ESS management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.